Arcus Biosciences (RCUS) Receivables - Net (2017 - 2025)

Arcus Biosciences' Receivables - Net history runs 8 years deep, the most recent figure standing at $3.0 million for Q1 2025.

• In Q1 2025, Receivables - Net fell 98.68% year-over-year to $3.0 million; the TTM figure through Mar 2025 stood at $3.0 million (down 98.68% YoY), while the FY2024 annual figure was $228.0 million, up 7500.0% from the prior year.
• Receivables - Net for Q1 2025 stood at $3.0 million, down from $228.0 million in the prior quarter.
• The five-year high for Receivables - Net was $228.0 million in Q1 2024, with the low at $3.0 million in Q3 2023.
• The 5-year median for Receivables - Net is $4.1 million (2021), against an average of $56.7 million.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net surged 7500.0% in 2024, then tumbled 98.68% in 2025.
• Arcus Biosciences' Receivables - Net stood at $4.9 million in 2021, then fell by 18.37% to $4.0 million in 2022, then retreated by 25.0% to $3.0 million in 2023, then soared by 7500.0% to $228.0 million in 2024, then sank by 98.68% to $3.0 million in 2025.
• Business Quant data shows RCUS's Receivables - Net at $3.0 million in Q1 2025, $228.0 million in Q4 2024, and $228.0 million in Q3 2024.